Robert C Klesges1, Rebecca A Krukowski2, James L Klosky3, Wei Liu4, Deo Kumar Srivastava4, James M Boyett4, Jennifer Q Lanctot5, Melissa M Hudson6, Charla Folsom5, Leslie L Robison5. 1. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN; rklesges@uthsc.edu. 2. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN; 3. Department of Psychology, St. Jude Children's Research Hospital, Memphis, TN; 4. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN; 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN; 6. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Abstract
INTRODUCTION: The purpose of this investigation was to determine the efficacy of two evidence-based tobacco quitlines in adult survivors of childhood cancer who regularly smoke cigarettes. METHODS: A total of 519 adult survivors of childhood cancer were randomized to either Proactive + 4 weeks of medication (Counselor-initiated intervention, n = 260) or a Reactive + 2 weeks of medication (Participant-initiated intervention, n = 259) condition. Both conditions received telephone counseling to quit smoking as well as nicotine replacement therapy. The primary outcome was biochemically verified (i.e. cotinine) point prevalence smoking cessation at 12 months follow-up. RESULTS: Participants randomized to the Proactive + 4 weeks of medication condition self-reported a higher rate of cessation than those survivors in the Reactive + 2 weeks of medication condition at 8 weeks (33.2% vs. 17.0%, p < .001), but cessation rates were not significantly different at 12 months (23.0% vs. 18.7%, p = .29). However, 80% of participants claiming abstinence failed biochemical verification, indicating marked falsification of self-reported smoking status. Adjusted cessation rates were less than 2% in both intervention conditions. CONCLUSIONS: Our results indicate that neither a Proactive + 4 weeks of medication or Reactive + 2 weeks of medication quitline significantly impacted long-term smoking cessation rates. Our results further indicate that self-reports of smoking status are unreliable in survivors of childhood cancer, a population in considerable need of tobacco abstinence. Rates of smoking cessation may be markedly overestimated in studies of childhood cancer survivors that rely on self-reports of tobacco abstinence, and future studies need to include biochemical verification of tobacco status in this population.
RCT Entities:
INTRODUCTION: The purpose of this investigation was to determine the efficacy of two evidence-based tobacco quitlines in adult survivors of childhood cancer who regularly smoke cigarettes. METHODS: A total of 519 adult survivors of childhood cancer were randomized to either Proactive + 4 weeks of medication (Counselor-initiated intervention, n = 260) or a Reactive + 2 weeks of medication (Participant-initiated intervention, n = 259) condition. Both conditions received telephone counseling to quit smoking as well as nicotine replacement therapy. The primary outcome was biochemically verified (i.e. cotinine) point prevalence smoking cessation at 12 months follow-up. RESULTS:Participants randomized to the Proactive + 4 weeks of medication condition self-reported a higher rate of cessation than those survivors in the Reactive + 2 weeks of medication condition at 8 weeks (33.2% vs. 17.0%, p < .001), but cessation rates were not significantly different at 12 months (23.0% vs. 18.7%, p = .29). However, 80% of participants claiming abstinence failed biochemical verification, indicating marked falsification of self-reported smoking status. Adjusted cessation rates were less than 2% in both intervention conditions. CONCLUSIONS: Our results indicate that neither a Proactive + 4 weeks of medication or Reactive + 2 weeks of medication quitline significantly impacted long-term smoking cessation rates. Our results further indicate that self-reports of smoking status are unreliable in survivors of childhood cancer, a population in considerable need of tobacco abstinence. Rates of smoking cessation may be markedly overestimated in studies of childhood cancer survivors that rely on self-reports of tobacco abstinence, and future studies need to include biochemical verification of tobacco status in this population.
Authors: Jack F Hollis; Timothy A McAfee; Jeffrey L Fellows; Susan M Zbikowski; Michael Stark; Karen Riedlinger Journal: Tob Control Date: 2007-12 Impact factor: 7.552
Authors: Clare Frobisher; David L Winter; Emma R Lancashire; Raoul C Reulen; Aliki J Taylor; Christine Eiser; Michael C G Stevens; Michael M Hawkins Journal: J Natl Cancer Inst Date: 2008-07-29 Impact factor: 13.506
Authors: Terry M Bush; Tim McAfee; Mona Deprey; Lisa Mahoney; Jeffrey L Fellows; Jennifer McClure; Cathryn Cushing Journal: Nicotine Tob Res Date: 2008-09 Impact factor: 4.244
Authors: Karen Emmons; Frederick P Li; John Whitton; Ann C Mertens; Raymond Hutchinson; Lisa Diller; Leslie L Robison Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 50.717
Authors: Karen M Emmons; Elaine Puleo; Ann Mertens; Ellen R Gritz; Lisa Diller; Frederick P Li Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 50.717
Authors: Ann C Mertens; Qi Liu; Joseph P Neglia; Karen Wasilewski; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Yutaka Yasui Journal: J Natl Cancer Inst Date: 2008-09-23 Impact factor: 11.816
Authors: I-Chan Huang; James L Klosky; Chelsea M Young; Sharon E Murphy; Kevin K Krull; DeoKumar Srivastava; Melissa M Hudson; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2018-06-01 Impact factor: 3.167
Authors: Kathryn L Taylor; Charlotte J Hagerman; George Luta; Paula G Bellini; Cassandra Stanton; David B Abrams; Jenna A Kramer; Eric Anderson; Shawn Regis; Andrea McKee; Brady McKee; Ray Niaura; Harry Harper; Michael Ramsaier Journal: Lung Cancer Date: 2017-02-15 Impact factor: 5.705
Authors: Alice Little Caldwell; Martha S Tingen; Joshua T Nguyen; Jeannette O Andrews; Janie Heath; Jennifer L Waller; Frank A Treiber Journal: Pediatrics Date: 2018-01 Impact factor: 7.124
Authors: Francisco I Salgado García; Karen J Derefinko; Zoran Bursac; Robert C Klesges; Jon O Ebbert; Catherine R Womack; Rebecca A Krukowski Journal: Contemp Clin Trials Date: 2018-11-13 Impact factor: 2.226
Authors: Todd M Gibson; Wei Liu; Gregory T Armstrong; Deo Kumar Srivastava; Melissa M Hudson; Wendy M Leisenring; Ann C Mertens; Robert C Klesges; Kevin C Oeffinger; Paul C Nathan; Leslie L Robison Journal: Cancer Date: 2015-08-19 Impact factor: 6.860
Authors: E Anne Lown; Nobuko Hijiya; Nan Zhang; Deo Kumar Srivastava; Wendy M Leisenring; Paul C Nathan; Sharon M Castellino; Katie A Devine; Kimberley Dilley; Kevin R Krull; Kevin C Oeffinger; Melissa M Hudson; Gregory T Armstrong; Leslie L Robison; Kirsten K Ness Journal: Cancer Date: 2016-06-03 Impact factor: 6.860
Authors: Stephanie B Dixon; Kari L Bjornard; Nicole M Alberts; Gregory T Armstrong; Tara M Brinkman; Wassim Chemaitilly; Matthew J Ehrhardt; Israel Fernandez-Pineda; Lisa M Force; Todd M Gibson; Daniel M Green; Carrie R Howell; Sue C Kaste; Anne C Kirchhoff; James L Klosky; Kevin R Krull; John T Lucas; Daniel A Mulrooney; Kirsten K Ness; Carmen L Wilson; Yutaka Yasui; Leslie L Robison; Melissa M Hudson Journal: CA Cancer J Clin Date: 2018-01-29 Impact factor: 508.702